BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: PI3K inhibitor BYL719|BIOLOGICAL: ado-trastuzumab emtansine|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: Northwestern University
Collaborators: Novartis|National Cancer Institute (NCI)